NEWAMSTERDAM PHARMA CO NV
NAMSNASDAQ🏆 #1751 by market capUS Equity
$20.75▼ $0.32 (−1.52%)
Market closed · at closeTrack NAMS
Get earnings, price moves & breaking news on Telegram
24h▼ 1.5%
7d▲ 5.3%
14d▲ 4.6%
30d▼ 14.7%
ytd▼ 40.8%
1y▼ 46.5%
🏦Market Cap
$2.48B
Small Cap
📈Revenue Growth (YoY)
-88.9%
Declining
📊Gross Margin
—
💵FCF Margin
1648.5%
Strong
⚖️P/S Ratio
353.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $20.58 – $21.68
- 52-Week Range
- $19.13 – $42.21
- Volume (shares)
- 71,097
- Avg Volume (shares)
- —
- Shares Outstanding
- 119.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 353.7x
- EPS (TTM)
- $-2.15
- Dividend Yield
- —
- Dilution (1yr)
- +17.9%
NEWAMSTERDAM PHARMA CO NV
NAMSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$23M▼ −50.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.7%▼ −0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$226M▲ +28.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$148M▼ −7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
114.4M▲ +17.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$490M▼ −$281M YoY
StockOtter · stockotter.spaceAbout NEWAMSTERDAM PHARMA CO NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.